Jack R. Andrews, MD

PSMA PET imaging has reshaped prostate cancer staging and biochemical-recurrence evaluation. This review covers FDA-approved tracers, key performance stats, clinical decision points, and emerging theranostic therapies such as Lu-177 Pluvicto and alpha emitters. Future directions include AI-guided PSMA quantification, novel biomarkers, and combination molecular-immunologic strategies.